Global Information
회사소개 | 문의 | 비교리스트

세계의 주의력결핍 과잉행동장애(ADHD) 치료제 시장(2019-2023년)

Global Attention deficit Hyperactivity Disorder (ADHD) Drugs Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 05월 상품 코드 851236
페이지 정보 영문 127 Pages
가격
US $ 2,500 ₩ 2,971,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,565,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,753,000 PDF (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,942,000 PDF (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 주의력결핍 과잉행동장애(ADHD) 치료제 시장(2019-2023년) Global Attention deficit Hyperactivity Disorder (ADHD) Drugs Market 2019-2023
발행일 : 2019년 05월 페이지 정보 : 영문 127 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 주의력결핍 과잉행동장애(ADHD) 치료제 시장은 주로 ADHD 이환율 상승에 의해 성장이 촉진될 전망입니다. 미국 질병통제센터(CDC) 조사에서는 2016년 2-17세의 약 9.4%가 ADHD 진단을 받았습니다. 세계 주의력결핍 과잉행동장애(ADHD) 치료제 시장은 2023년까지 약 6%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

세계의 주의력결핍 과잉행동장애(ADHD: Attention deficit Hyperactivity Disorder) 치료제 시장을 조사했으며, 시장 개요, 제품 및 지역별 시장 규모 추이와 예측, 시장 성장요인 및 과제 분석, 시장 기회, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 주요 요약

제2장 보고서의 범위

제3장 시장 상황

  • 시장 생태계
  • 시장 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모
  • 시장 규모 및 예측

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급업체의 협상력
  • 신규 참여업체의 위협
  • 대체품의 위협
  • 경쟁사의 위협
  • 시장 현황

제6장 시장 세분화 : 제품별

  • 시장 세분화 : 제품별
  • 시장 비교 : 제품별
  • 중추자극제
  • 비중추자극제
  • 시장 기회 : 제품별

제7장 고객 상황

제8장 지역 상황

  • 시장 분석 : 지역별
  • 시장 비교 : 지역별
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 시장 성장 기여국가
  • 시장 기회

제9장 의사결정 프레임워크

제10장 성장요인과 과제

  • 시장 성장요인
  • 시장의 과제

제11장 시장 동향

제12장 벤더 상황

  • 개요
  • 파괴적 혁신
  • 경쟁 시나리오

제13장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Amneal Pharmaceuticals Inc.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • NEOS Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.

제14장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제15장 TECHNAVIO에 대해

LSH 19.05.30

About this market

The rising incidence rate of ADHD among children is one of the critical factors that will trigger the growth of the attention deficit hyperactivity disorder drugs market. The expansion of the patient pool with positive ADHD symptoms is fueling the demand for ADHD therapies. As per the CDC, in 2016. Approximately 9.4% of children aged 2-17 years were diagnosed with ADHD. Thus, a significant patient pool (aged between 12 and 17 years) rely on medications. This is expected to rise further with the increasing prevalence of the disease, thereby contributing to the growth of the market during the forecast period. Technavio's analysts have predicted that the attention deficit hyperactivity disorder (ADHD) drugs market will register a CAGR of almost 6% by 2023.

Market Overview

Rising government support

The global ADHD drugs market is currently witnessing an increase in the number of government initiatives to promote the awareness of the disease and to fund drug development in the area of mental health therapeutics. Additionally, the Centers for Disease Control and Prevention (CDC) supports the National Resource Center (NRC) on ADHD, a program designed to help children and adults with ADHD. The NRC program provides information, resources, and advice to parents on how to help their children with ADHD. Thus, the rising government support to help people with ADHD is expected to drive the growth of the market during the forecast period.

Lack of patient compliance with ADHD treatment

The pharmacological (medications) treatment with neuro-stimulant drugs is considered as the gold standard for the treatment of ADHD in children and adults. However, the multiple dosing regimens associated with neuro-stimulant drugs, such as methylphenidate and amphetamine, and the timely dosing and long duration of the treatment are leading to a decrease in the patient compliance with these drugs. This leads to a decline in the consumption of ADHD drugs, thereby impeding the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the attention deficit hyperactivity disorder (ADHD) drugs market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly fragmented. The presence of several companies, including Johnson & Johnson Services Inc. and NEOS Therapeutics Inc. makes the competitive environment quite intense. Factors such as the rising incidence rate of ADHD among children and the increasing government support will provide considerable growth opportunities to attention deficit hyperactivity disorder drugs manufactures. Amneal Pharmaceuticals Inc., Eli Lilly and Co., and Takeda Pharmaceutical Co. Ltd. are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Stimulants - Market size and forecast 2018-2023
  • Non-stimulants - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amneal Pharmaceuticals Inc.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • NEOS Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global central nervous system (CNS) disorders drugs market
  • Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Stimulants - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Stimulants - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Non-stimulants - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Non-stimulants - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by product
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Mental illness scenario in the US in 2016
  • Exhibit 29: CDC statistics on the incidence rate of ADHD and other disorder among children aged 2-17 years in 2016
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: Prevalence rate of mental disorder in the Australian population aged 4 to 17 years, 2016
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: ADHD scenario in the US in 2016
  • Exhibit 45: ADHD treatment scenario by age group
  • Exhibit 46: Adoption towards pharmacological therapy among ADHD children in the US, 2011
  • Exhibit 47: Prevalence scenario of AMI in the US, 2017
  • Exhibit 48: Prevalence scenario of SMI in the US, 2017
  • Exhibit 49: Factors leading to noncompliance with drug therapy
  • Exhibit 50: Management of side-effects associated with ADHD medication
  • Exhibit 51: Impact of drivers and challenges
  • Exhibit 52: Vendor landscape
  • Exhibit 53: Landscape disruption
  • Exhibit 54: Vendors covered
  • Exhibit 55: Vendor classification
  • Exhibit 56: Market positioning of vendors
  • Exhibit 57: Amneal Pharmaceuticals Inc. - Vendor overview
  • Exhibit 58: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibit 59: Amneal Pharmaceuticals Inc. - Organizational developments
  • Exhibit 60: Amneal Pharmaceuticals Inc. - Segment focus
  • Exhibit 61: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibit 62: Amneal Pharmaceuticals Inc. - Key customers
  • Exhibit 63: Eli Lilly and Co. - Vendor overview
  • Exhibit 64: Eli Lilly and Co. - Business segments
  • Exhibit 65: Eli Lilly and Co. - Organizational developments
  • Exhibit 66: Eli Lilly and Co. - Geographic focus
  • Exhibit 67: Eli Lilly and Co. - Segment focus
  • Exhibit 68: Eli Lilly and Co. - Key offerings
  • Exhibit 69: Eli Lilly and Co. - Key customers
  • Exhibit 70: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 71: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 72: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 73: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 74: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 75: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 76: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 77: NEOS Therapeutics Inc. - Vendor overview
  • Exhibit 78: NEOS Therapeutics Inc. - Business segments
  • Exhibit 79: NEOS Therapeutics Inc. - Organizational developments
  • Exhibit 80: NEOS Therapeutics Inc. - Key offerings
  • Exhibit 81: NEOS Therapeutics Inc. - Key customers
  • Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 86: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 87: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 88: Validation techniques employed for market sizing
  • Exhibit 89: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q